» Articles » PMID: 30258433

-Induced Human IL-10 B Cells Do Not Show a Subset-Defining Marker Signature and Plastically Co-express IL-10 With Pro-Inflammatory Cytokines

Overview
Journal Front Immunol
Date 2018 Sep 28
PMID 30258433
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

Regulatory B cells (Breg) have been described as a specific immunological subsets in several mouse models. Identification of a human counterpart has remained troublesome, because unique plasma membrane markers or a defining transcription factor have not been identified. Consequently, human Bregs are still primarily defined by production of IL-10. In this study, we sought to elucidate if induced human IL-10 producing B cells are a dedicated immunological subset. Using deep immune profiling by multicolor flow cytometry and t-SNE analysis, we show that the majority of cells induced to produce IL-10 co-express pro-inflammatory cytokines IL-6 and/or TNFα. No combination of markers can be identified to define human IL-10TNFαIL-6 B cells and rather point to a general activated B cell phenotype. Strikingly, upon culture and restimulation, a large proportion of formerly IL-10 producing B cells lose IL-10 expression, showing that induced IL-10 production is not a stable trait. The combined features of an activated B cell phenotype, transient IL-10 expression and lack of subset-defining markers suggests that -induced IL-10 producing B cells are not a dedicated subset of regulatory B cells.

Citing Articles

The current understanding of the phenotypic and functional properties of human regulatory B cells (Bregs).

Ahsan N, Lourenco S, Psyllou D, Long A, Shankar S, Bashford-Rogers R Oxf Open Immunol. 2024; 5(1):iqae012.

PMID: 39346706 PMC: 11427547. DOI: 10.1093/oxfimm/iqae012.


Thioredoxin is a metabolic rheostat controlling regulatory B cells.

Bradford H, McDonnell T, Stewart A, Skelton A, Ng J, Baig Z Nat Immunol. 2024; 25(5):873-885.

PMID: 38553615 PMC: 11065695. DOI: 10.1038/s41590-024-01798-w.


Immune reconstitution following alemtuzumab therapy is characterized by exhausted T cells, increased regulatory control of proinflammatory T cells and reduced B cell control.

von Essen M, Hojsgaard Chow H, Holm Hansen R, Buhelt S, Sellebjerg F Front Immunol. 2023; 14:1249201.

PMID: 37744364 PMC: 10512074. DOI: 10.3389/fimmu.2023.1249201.


Phorbol-12-myristate-13-acetate is a potent enhancer of B cells with a granzyme B regulatory phenotype.

Veh J, Mangold C, Felsen A, Ludwig C, Gerstner L, Reinhardt P Front Immunol. 2023; 14:1194880.

PMID: 37588597 PMC: 10426744. DOI: 10.3389/fimmu.2023.1194880.


The Molecular Role of Immune Cells in Dilated Cardiomyopathy.

Wang E, Zhou R, Li T, Hua Y, Zhou K, Li Y Medicina (Kaunas). 2023; 59(7).

PMID: 37512058 PMC: 10385992. DOI: 10.3390/medicina59071246.


References
1.
Chung J, Silverman M, Monroe J . Transitional B cells: step by step towards immune competence. Trends Immunol. 2003; 24(6):343-9. DOI: 10.1016/s1471-4906(03)00119-4. View

2.
Linsley P, Brady W, Grosmaire L, Aruffo A, Damle N, Ledbetter J . Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J Exp Med. 1991; 173(3):721-30. PMC: 2118836. DOI: 10.1084/jem.173.3.721. View

3.
Matsushita T, Tedder T . Identifying regulatory B cells (B10 cells) that produce IL-10 in mice. Methods Mol Biol. 2010; 677:99-111. DOI: 10.1007/978-1-60761-869-0_7. View

4.
Lighaam L, Vermeulen E, Bleker T, Meijlink K, Aalberse R, Barnes E . Phenotypic differences between IgG4+ and IgG1+ B cells point to distinct regulation of the IgG4 response. J Allergy Clin Immunol. 2013; 133(1):267-70.e1-6. DOI: 10.1016/j.jaci.2013.07.044. View

5.
Blair P, Norena L, Flores-Borja F, Rawlings D, Isenberg D, Ehrenstein M . CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients. Immunity. 2010; 32(1):129-40. DOI: 10.1016/j.immuni.2009.11.009. View